毕得医药
(688073)
| 流通市值：63.62亿 | | | 总市值：63.62亿 |
| 流通股本：9088.29万 | | | 总股本：9088.29万 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,051,265,091.19 | 682,837,408.72 | 323,276,733.74 | 1,323,810,726.7 |
| 营业收入 | 1,051,265,091.19 | 682,837,408.72 | 323,276,733.74 | 1,323,810,726.7 |
| 二、营业总成本 | 820,928,608.08 | 533,913,560.35 | 262,853,915.44 | 1,107,810,422.06 |
| 营业成本 | 528,257,152.6 | 338,522,705.15 | 165,248,354.14 | 734,238,643.78 |
| 税金及附加 | 6,188,024.2 | 4,094,821.94 | 1,095,770.37 | 5,503,022.81 |
| 销售费用 | 109,466,767.29 | 72,670,855.63 | 35,239,041.36 | 150,394,336.32 |
| 管理费用 | 100,599,229.09 | 65,839,929.66 | 33,618,012.56 | 140,296,473.27 |
| 研发费用 | 48,177,479.31 | 31,749,462.69 | 14,988,972.72 | 62,715,609.01 |
| 财务费用 | 28,239,955.59 | 21,035,785.28 | 12,663,764.29 | 14,662,336.87 |
| 其中:利息费用 | 3,074,607.72 | 2,099,434.08 | 1,097,266.76 | 5,801,324.09 |
| 其中:利息收入 | 10,031,016.55 | 7,621,481.29 | 3,788,795.59 | 11,358,501.38 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,567,143.83 | 1,633,661.29 | 610,095.9 | 2,599,122.99 |
| 加:投资收益 | 2,015,285.64 | 1,176,349.53 | 404,071.08 | 7,983,317.65 |
| 资产处置收益 | 4,676,896.92 | 4,842,482.5 | 4,877,893.13 | 3,898,219.62 |
| 资产减值损失(新) | -32,355,386.42 | -21,389,122.23 | -8,175,314.71 | -41,022,275.45 |
| 信用减值损失(新) | -3,855,401.85 | -2,756,015.3 | -749,108.14 | -3,948,628.78 |
| 其他收益 | 4,974,595.89 | 4,748,891.78 | 4,305,425.12 | 10,988,043.25 |
| 四、营业利润 | 208,359,617.12 | 137,180,095.94 | 61,695,880.68 | 196,498,103.92 |
| 加:营业外收入 | 497,534.53 | 364,208.06 | 259,787.39 | 1,276,258.18 |
| 减:营业外支出 | 755,542.7 | 588,999.38 | 575,736.04 | 2,346,878.68 |
| 五、利润总额 | 208,101,608.95 | 136,955,304.62 | 61,379,932.03 | 195,427,483.42 |
| 减:所得税费用 | 44,166,607.86 | 33,651,307.81 | 14,550,791.63 | 43,687,831.83 |
| 六、净利润 | 163,935,001.09 | 103,303,996.81 | 46,829,140.4 | 151,739,651.59 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 163,935,001.09 | 103,303,996.81 | 46,829,140.4 | 151,739,651.59 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 163,935,001.09 | 103,303,996.81 | 46,829,140.4 | 151,739,651.59 |
| 扣除非经常损益后的净利润 | 142,532,180.26 | 83,602,200.75 | 39,924,621.68 | 132,315,476.46 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.9 | 1.2 | 0.54 | 1.75 |
| (二)稀释每股收益 | 1.9 | 1.19 | 0.54 | 1.73 |
| 八、其他综合收益 | 5,080,381.7 | 4,409,705.66 | 3,042,449.36 | 6,977,647.18 |
| 归属于母公司股东的其他综合收益 | 5,080,381.7 | 4,409,705.66 | 3,042,449.36 | 6,977,647.18 |
| 九、综合收益总额 | 169,015,382.79 | 107,713,702.47 | 49,871,589.76 | 158,717,298.77 |
| 归属于母公司股东的综合收益总额 | 169,015,382.79 | 107,713,702.47 | 49,871,589.76 | 158,717,298.77 |
| 公告日期 | 2026-10-30 | 2026-08-28 | 2026-04-30 | 2026-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |